C0013089||Doxorubicin
C0600688||Toxicity
C0025929||Mouse
C0018120||Ovarian Follicle
C0243107||Development
C0312431||Hormone Secretion
C1160520||Oocyte Maturation
C0013089||Doxorubicin
C0013089||Doxorubicin
C0003392||anticancer medications
C0015895||fertility
C0018120||ovarian follicles
C0600688||toxicity
C0013089||Doxorubicin
C0018120||follicle
C0243107||development
C1160520||oocyte maturation
C0018017||objective
C0086418||human
C0013089||Doxorubicin
C0018120||follicular
C0243107||developmental
C0430400||cultured
C0737234||multilayered secondary mouse follicles
C0013089||Doxorubicin
C0018120||follicle
C0243107||development
C0312431||hormone secretion
C1160520||oocyte maturation
C0013089||Doxorubicin
C0600688||toxicity
C1155902||follicle growth
C0312431||secretion
C0014912||17Î²-estradiol
C0014912||E2
C0013089||Doxorubicin
C0012860||DNA damage
C0162638||apoptosis
C0018120||follicle
C1257909||somatic cells
C0029045||oocytes
C0243144||uptake
C0013089||Doxorubicin
C1257909||somatic cells
C0017471||germ cells
C0018120||Follicles
C0013089||Doxorubicin
C0029045||oocyte
C1155832||metaphase II
C1155832||metaphase II
C1160520||oocyte maturation
C0013089||Doxorubicin
C1155832||metaphase II
C0029045||oocytes
C0205161||abnormal
C1166795||spindle
C0008633||chromosome
C1515655||in vivo
C0600688||toxicity
C1160520||oocyte meiotic maturation
C0025929||CD-1 mice
C0013089||Doxorubicin
C1160520||oocyte maturation
C2603343||study
C0013089||Doxorubicin
C0600688||toxicity
C0018120||ovarian follicle
C0243107||development
C0312431||hormone secretion
C1160520||oocyte maturation
C0278049||female reproductive
C0678896||endocrine functions